Saturday, June 20, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 877 of 1,261

  1. US 8415387

    Modulators of ATP-binding cassette transporters

    Vertex Pharmaceuticals Incorporated · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  2. US 8415332

    Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

    Teva Womans's Health, Inc. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  3. US 8415302

    Surgical applications for BMP binding protein

    The Regents of the University of California · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  4. US 8415396

    Colchine compositions and methods

    Takeda Pharmaceuticals U.S.A., Inc. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  5. US 8414909

    Drug releasing coatings for medical devices

    Lutonix, Inc. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  6. US 8415481

    Crystalline form of febuxostat

    Teva Pharmaceuticals USA, Inc. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  7. US 8415458

    Modified vitamin K-dependent polypeptides

    Regents of the University of Minnesota · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  8. US 8415457

    Modified vitamin K-dependent polypeptides

    Regents of the University of Minnesota · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  9. US 8414890

    Human antibodies to human RANKL, encoding nucleic acids and methods of treatment

    REGENERON PHARMACEUTICALS, INC. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  10. US 8415365

    Compositions and methods for inhibition of the JAK pathway

    Rigel Pharmaceuticals, Inc. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  11. US 8415294

    Cyclodepsipeptides with antineoplastic activity and methods of using to inhibit cancer and microbial growth

    THE ARIZONA BOARD OF REGENTS · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  12. US 8415456

    Substituted IL-15 polypeptides

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  13. US 8415395

    Colchicine compositions and methods

    Takeda Pharmaceuticals U.S.A., Inc. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  14. US 8415370

    Spiro-oxindole compounds and their uses as therapeutic agents

    Xenon Pharmaceuticals Inc. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  15. US 8415384

    Reducing myocardial reperfusion injury by the combination therapy of protein kinase A activation and B1-adrenergic receptor blockade

    The Board of Regents of the University of Texas System · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  16. US 8415343

    Compositions and methods for inhibiting the proliferation of cells

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  17. US 8415400

    Cross-linked ionic core micelles

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  18. US 8415368

    Acid secretion inhibitor

    Takeda Pharmaceutical Company Limited · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  19. US 8415135

    Lactobacillus plantarum and uses thereof

    China Medical University · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  20. US 8415323

    MicroRNAs for inhibiting viral replication

    The Regents of the University of California · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  21. US 8415314

    Methods for treating multiple sclerosis using antisense oligonucleotides

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  22. US 8415293

    Peptide mediators of cholesterol efflux

    The Regents of the University of California · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  23. US 8415097

    Tumor suppressor gene, p47ING3

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

  24. US 8414918

    Stable imatinib compositions

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Apr 9, 2013 · Expires Apr 4, 2033

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.